
**What is Claimed:**

1. The use of a pharmaceutical combination consisted of TSL-1502M and SN38 in the manufacture of a medicament for preventing and treating colon tumor, wherein the structure of TSL-1502M is as follows:



Formula II

wherein the combination comprises a combination of pharmaceutical preparations individually containing TSL-1502M and SN38, wherein the two preparations are packaged together.

2. The use according to claim 1, wherein the pharmaceutical combination is an injectable preparation, in a unit dose form, with each unit dose comprising 0.1-2000mg of pharmaceutically active ingredient.

3. The use according to claim 1, wherein the combination comprises TSL-1502M and SN38, in a weight ratio of 1∶1000 to 1000∶1.

4. The use according to claim 1, wherein the dose of each drug is in a pharmaceutically effective amount.

5. The use according to claim 1, wherein the pharmaceutical combination is in any ingestible pharmaceutical form .

6. The use according to claim 1, wherein the method of using comprises the following steps: separately preparing the required amounts of TSL-1502M and SN38 into injectable preparations for seperate injection.

7. The use according to any one of claims 1-8, comprises the following steps: preparing the required amount of TSL-1502M and SN38 together or respectively as pharmaceutical active ingredients into a pharmaceutical preparation combination which can be taken according to the conventional technology of pharmacy.

8. The use according to claim 9, wherein the dosage form of the pharmaceutical combination is injectable preparation, without adding excipients or adding one or more pharmacetical excipients such as glucose, lactose, mannitol, sodium chloride, hydroxypropyl-B-cyclodextrin and the like, and formulated into an injectable preparation.